Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held company developing therapies based on interleukin-12 (IL-12) as a radiation medical countermeasure and for the treatment of chemotherapy-induced polycytopenia (ChIP), announces receipt of notification from the Biomedical Advanced Research & Development Authority (BARDA) of the U.S. Department of Health and Human Services (DHHS) of its intent to exercise an option for continued development of HemaMax™ (recombinant human interleukin 12 or rHuIL-12) for the treatment for hematopoietic syndrome of acute radiation sickness (HSARS). The goal of the option is to conduct animal studies comparing the effectiveness of HemaMax™ with granulocyte colony-stimulating factor (G-CSF) as well as assessing the effectiveness of a combination of HemaMax™ and G-CSF as a treatment for HSARS. This study will also advance HemaMax™ toward a Biologics License Application (BLA) submission by fulfilling the U.S. Food and Drug Administration’s (FDA) requirement for a bridging study to evaluate efficacy of HemaMax™ with Level 1 supportive care (use of antibiotics and fluids).
Help employers find you! Check out all the jobs and post your resume.
